Abstract
Cytosolic determinations of cathepsin-D (cath-D), urokinase plasminogen activator (uPA) and its specific inhibitor PAI-1 have shown an association with adverse prognosis in breast cancer. Our aim was to study the distribution of these markers in small axillary node-negative breast carcinomas using immunohistochemistry and relate the semiquantitative results to known prognostic factors, the expression of tenascin-C (Tn-C) in invasion border of the tumour and prognosis. All the 158 women (159 tumours) were treated with breast conserving surgery and postoperative radiotherapy. Cytoplasmic immunoreactivity for cath-D was seen in carcinoma cells in 47% and in stromal cells in 44%. Nearly all tumours expressed uPA and PAI-1, which were categorized to cytoplasmic expression in carcinoma cells and diffuse stromal expression and quantified – / + / ++ / +++ and further dichotomized for purposes of analysis. Expression of uPA and PAI-1 in stromal fibroblasts was recorded as – / +. Cytoplasmic and stromal cell cath-D contents were associated with grade, proliferation, Tn-C expression in the tumour invasion border and the development of distant metastasis. In multivariate analysis stromal cath-D proved to be an independent prognostic factor for metastasis. Stromal expression of uPA was associated with an increased risk of local recurrence; otherwise high levels of uPA did not associate with other prognostic factors nor with prognosis. Fibroblastic expression of PAI-1 showed an association with both local and distant disease recurrence. However, no consistent association between the immunohistochemically quantified uPA and PAI-1 and prognosis was found. In conclusion, immunohistochemical determination of cath-D seems to be a viable method to predict a higher risk of metastasis but not local recurrence in small axillary node-negative breast carcinomas.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aaltonen, M., Lipponen, P., Kosma, V-M, Aaltomaa, S. & Syrjänen, K. (1995) Prognostic value of cathepsin D expression in female breast cancer. Anticancer Res 15: 1033–1038.
Alo, P. L., Visca, P., Marci, A., Mangoni, A., Botti, C. & Tondo, U. D. (1996) Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77: 474–482.
Armas, O. A., Gerald, W. L., Lesser, M. L., Arroyo, C. D., Norton, L. & Rosen, P. P. (1994) Immunohistochemical detection of cathepsin D in T2N0M0 breast carcinoma. Am J Surg Pathol 18: 158–166.
Bernstein, L. R. & Liotta, L. A. (1994) Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis. Curr Opin Oncol 6: 106–113.
Bianchi, E., Cohen, R. L., Dai, A., Thor, A. T., Shuman, M. A. & Smith, H. S. (1995) Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer 60: 597–603.
Bouchet, C., Spyratos, F., Martin, P. M., Hacène, K., Gentile, A. & Oglobine, J. (1994) Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398–405.
Cardiff, R. D. (1994) Cathepsin D and breast cancer: useful? (editorial). Hum Pathol 25: 847–848.
Castiglioni, T., Merino, M. J., Elsner, B., Lah, T. T., Sloane, B. F. & Emmert-Buck, M. R. (1994) Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum Pathol 25: 857–862.
Charpin, C., Devictor, B., Bonnier, P., Andrac, L., Lavaut, M. N., Allasia, C. & Piana, L. (1993) Cathepsin D immunocytochemical assays in breast carcinomas: image analysis and correlation to prognostic factors. J Pathol 170: 463–470.
Christensen, L., Simonsen, A. C. W., Heegaard, C. W., Moestrup, S. K., Andersen, J. A. & Andreasen, P. A. (1996) Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen activator inhibitor, urokinase receptor and alfa-2-macroglobulin receptor in human breast carcinomas. Int J Cancer 66: 441–452.
Costantini, V., Sidoni, A., Deveglia, R., Cazzato, O. A., Bellezza, G., Ferri, I., Bucciarelli, E. & Nenci, G. G. (1996) Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression. Cancer 77: 1079–1088.
Dano, K., Andreasen, P. A., Grondal-Hansen, J., Kristensen, P., Nielsen, L. S. & Skriver, L. (1985) Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139–266.
Domagala, W., Striker, G., Szadowska, A., Dukowicz, A., Weber, K. & Osborn, M. (1992) Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. Am J Pathol 141: 1003–1012.
Duffy, M. J., O’Grady, P., Devaney, D., O’Siorain, L., Fennelly, J. J. & Lijnen, H. J. (1988) Urokinase-plasminogen activator, a marker for aggressive breast carcinomas: preliminary report. Cancer 62: 531–533.
Duffy, M. J., Reilly, D., O’Sullivan, C., O’Higgins, N., Fennelly, J. J. & Andreasen, P. (1990) Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827–6829.
Duffy, M. J., Brouillet, J-P, Reilly, D., McDermott, E., O’Higgins, N., Fennelly, J. J., Maudelonde, T. & Rochefort, H. (1991) Cathepsin D concentration in breast cancer cytosols: correlation with biochemical, histological, and clinical findings. Clin Chem 37: 101–104.
Duffy, M. J., Reilly, D., Brouillet, J-P, McDermott, E. W. M., Faul, C., O’Higgins, N., Fennelly, J. J., Maudelonde, T. & Rochefort, H. (1992) Cathepsin D concentration in breast cancer cytosols: correlation with disease-free interval and overall survival. Clin Chem 38: 2114–2116.
Fernö, M., Baldetorp, B., Borg, Å, Brouillet, J-P, Olsson, H., Rochefort, H., Sellberg, G., Sigurdsson, H., Killander, D. & Group, tSSBC (1994) Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. Eur J Cancer 30A: 2042–2048.
Ferrandina, G., Scambia, G., Bardelli, F., Panici, P. B., Mancuso, S. & Messori, A. (1997) Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer 76: 661–666.
Foekens, J. A., Schmitt, M., von Putten, W. L. J., Peters, H. A., Bontenbal, M., Jänicke, F. & Klijn, J. G. M. (1992) Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101–6105.
Foekens, J. A., Schmitt, M., von Putten, W. L. J., Peters, H. A., Kramer, M. D., Jänicke, F. & Klijn, J. G. M. (1994) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648–1658.
Foucré, D., Bouchet, C., Hacène, K., Pourreau-Schneider, N., Gentile, A., Martin, P. M., Desplaces, A. & Oglobine, J. (1991) Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer 64: 926–932.
Granata, G., Coradini, D., Cappelletti, V. & Fronzo, G. D. (1991) Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. Eur J Cancer 27: 970–972.
Grondal-Hansen, J., Christensen, I. J., Rosenquist, C., Brunner, N., Mouridsen, H. T., Dano, K. & Blichert-Toft, M. (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513–2521.
Grondal-Hansen, J., Hilsenbeck, S. G., Christensen, I. J., Clark, G. M., Osborne, C. K. & Brunner, N. (1997) Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat 43: 153–163.
Henry, J. A., McCarthy, A. L., Angus, B., Westley, B. R., May, F. E. B., Nicholson, S., Cairns, J., Harris, A. L. & Horne, C. H. W. (1990) Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. Cancer 65: 265–271.
Hofmann, R., Lehmer, A., Buresch, M., Hartung, R. & Ulm, K. (1996) Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 78: 487–492.
Isola, J., Weitz, S., Visakorpi, T., Holli, K., Shea, R., Khabbaz, N. & Kallioniemi, O-P (1993) Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol 11: 36–43.
Jahkola, T., Toivonen, T., von Smitten, K., Blomqvist, C. & Virtanen, I. (1996) Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer (Pred Oncol) 69: 445–447.
Jahkola, T., Toivonen, T., Virtanen, I., von Smitten, K., Nordling, S., von Boguslawski, K., Haglund, C., Nevanlinna, H. & Blomqvist, C. (1998a) Tenascin-C expression in invasion border of early breast cancer – a predictor of local and distant recurrence. Br J Cancer 78: 1507–1513.
Jahkola, T., Toivonen, T., Nordling, S., von Smitten, K. & Virtanen, I. (1998b) Expression of tenascin-C in intraductal carcinoma of human breast: relation to invasion. Eur J Cancer 34: 1687–1692.
Jänicke, F., Schmitt, M., Pache, L., Ulm, K., Harbeck, N., Höfler, H. & Graeff, H. (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195–208.
Jänicke, F., Schmitt, M., Ulm, K., Gössner, W. & Graeff, H. (1989) Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 334: 1049
Joensuu, H., Toikkanen, S. & Isola, J. (1995) Stromal cell cathepsin D expression and long-term survival in breast cancer. Br J Cancer 71: 155–159.
Kandalaft, P. L., Chang, K. L., Ahn, C. W., Traweek, S. T., Mehta, P. & Battifora, H. (1993) Prognostic significance of immunohistochemical analysis of cathepsin D in low-stage breast cancer. Cancer 71: 2756–2763.
Keski-Oja, J., Lohi, J., Tuuttila, A., Tryggvason, K. & Vartio, T. (1992) Proteolytic processing of the 72,000-Da type IV collagenase by urokinase plasminogen activator. Exp Cell Res 202: 471–476.
Kute, T. E., Shao, Z. M., Sugg, N. K., Long, R. T., Rusell, G. B. & Case, L. D. (1991) Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 52: 5198–5203.
Liotta, L. A., Tryggvason, K., Garbisa, S., Robey, P. G. & Abe, S. (1981) Partial purification and characterization of a neutral protease which cleaves type IV collagen. Biochemistry 20: 100–104.
Mulcahy, H. E., Duffy, M. J., Gibbons, D., McCarthy, P., Parfrey, N. A., O’Donoghue, D. P. & Sheahan, K. (1994) Urokinase-type plasminogen activator and outcome in Dukes’ B colorectal cancer. Lancet 344: 583–584.
Namer, M., Ramaioli, A., Fontana, X., Etienne, M-C, Héry, M., Jourlait, A., Milano, G., Frenay, M., Francois, E. & Lapalus, F. (1991) Prognostic value of total cathepsin D in breast tumors. Breast Cancer Res Treat 19: 85–93.
O’Donoghue, AEMA, Poller, D. N., Bell, J. A., Galea, M. H., Elston, C. W., Blamey, R. W. & Ellis, I. O. (1995) Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells. Breast Cancer Res Treat 33: 137–145.
Pujol, P., Maudelonde, T., Daures, J-P, Rouanet, P., Brouillet, J-P, Pujol, H. & Rochefort, H. (1993) A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 71: 2006–2012.
Ravdin, P. M. (1993) Evaluation of cathepsin D as a prognostic factor in breast cancer. (review). Breast Cancer Res Treat 24: 219–226.
Ravdin, P. M., Tandon, A. K., Allred, C., Clark, G. M., Fuqua, S. A. W., Hilsenbeck, S. H., Chamness, G. C. & Osborne, C. K. (1994) Cathepsin D by Western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 12: 467–474.
Razumovic, J. J., Stojkovic, R. R., Petrovecki, M. & Gamulin, S. (1997) Correlation of two methods for determination of cathepsin D in breast carcinoma (immunohistochemistry and ELISA in cytosol). Breast Cancer Res Treat 43: 117–122.
Reilly, D., Christensen, L., Duch, M., Nolan, N., Duffy, M. J. & Andreasen, P. A. (1992) Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 50: 208–214.
Rochefort, H. (1996) The prognostic value of cathepsin D in breast cancer. A long road to the clinic (editorial). Eur J Cancer 32A: 7–8.
Roger, P., Montcourrier, P., Maudelonde, T., Brouillet, J-P, Pages, A., Laffargue, F. & Rochefort, H. (1994) Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay. Hum Pathol 25: 863–871.
Spyratos, F., Brouillet, J-P, Defrenne, A., Hacene, K., Rouessé, J., Maudelonde, T., Brunet, M., Andrieu, C., Desplaces, A. & Rochefort, H. (1989) Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet 334: 1115–1118.
Spyratos, F., Martin, P-M, Hacène, K., Romain, S., Andrieu, C., Ferrero-Pous, M., Deytieux, S., Doussal, V. L., Tubiana-Hulin, M. & Brunet, M. (1992) Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84: 1266–1272.
Tandon, A. K., Clark, G. M., Chamness, G. C., Chirgwin, J. M. & McGuire, W. L. (1990) Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297–302.
Tetû, B., Brisson, J., Côté, C., Brisson, S., Potvin, D. & Roberge, N. (1993) Prognostic significance of cathepsin D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer 55: 429–435.
Thorpe, S. M., Rochefort, H., Garcia, M., Freiss, G., Christensen, I. J., Khalaf, S., Paolucci, F., Pau, B., Rasmussen, B. B. & Rose, C. (1989) Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49: 6008–6014.
Westley, B. R. & May, F. E. B. (1996) Cathepsin D and breast cancer. Eur J Cancer 32A: 15–24.
Winstanley, J. H. R., Leinster, S. J., Cooke, T. G., Westley, B. R., Platt-Higgins, A. M. & Rudland, P. S. (1993) Prognostic significance of cathepsin-D in patients with breast cancer. Br J Cancer 67: 767–772.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Jahkola, T., Toivonen, T., Smitten, K. et al. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors. Br J Cancer 80, 167–174 (1999). https://doi.org/10.1038/sj.bjc.6690336
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690336
Keywords
This article is cited by
-
Tenascin-C and fibronectin expression divide early stage tongue cancer into low- and high-risk groups
British Journal of Cancer (2017)
-
Expression and prognostic value of plasminogen activator inhibitor type 1 in node-negative breast cancer
The Chinese-German Journal of Clinical Oncology (2008)
-
The prognostic significance of a combined determination of cathepsin D and estrogen receptors in breast carcinomas with positive axillary lymph nodes
Chinese Journal of Clinical Oncology (2006)
-
Tissue-Type plasminogen activator (tPA) in breast cancer: relationship with clinicopathological parameters and prognostic significance
Breast Cancer Research and Treatment (2005)
-
Case reports of malignant mucocele-like lesions
Breast Cancer (2002)